Kathleen D. LaPorte
Independent Non Executive DirectorMs. Kathleen D. LaPorte, M.B.A. also known as Kathy, serves as an Independent Director at Q32 Bio Inc. since July 2021. She is an Independent Director of CERo Therapeutics Holdings, Inc since February 14, 2024 and has been Director of CERo Therapeutics Inc. from February 2024. She serves as an Independent Director at 89bio, Inc. since November 03, 2021. She served as a Director of PBAX from October 2021 until February 2024. Ms. LaPorte has been Independent Director at Bolt Biotherapeutics Inc. since December 2020.She previously served on the California Institute for Regenerative Medicine, Ms. LaPorte has been an Independent Non-Executive Director of Precipio, Inc. since August 7, 2018. Ms. LaPorte served as the Chief Executive Officer since July 2015 to July 2016 and President of Nodality, Inc. since July 2015. She has experience in building and operating private and public biotech companies. Ms. LaPorte was a Venture Partner at New Leaf Venture Partners and was one of the Founders since 2005 until 2014, collaborating on sourcing of opportunities with an emphasis on the Information Convergence sector. She holds experience in biotechnology and biopharmaceutical industries. She served as an Independent Director at Phoenix Biotech Acquisition Corp. since June 2021 until February 2024. She was Founding Partner at the firm. Ms. LaPorte is an executive and VC with experience building innovative life sciences companies. Her focus is on pharmaceutical, biopharmaceutical and diagnostic investments. Ms. LaPorte was one of the Founders of CareInSync Corporation and served as its Founding Partner and Partner. She served as Advisor at CareInSync Corporation. She served as the Chief Business Officer of Nodality, Inc. from August 6, 2014 to July 2015. She was co-Founder of Health Tech Capital. Ms. LaPorte is an angel Investor in the digital health space focusing on evaluating and mentoring start-ups developing digital technology solutions for healthcare consumers, providers, payers and the pharmaceutical/medical device industries. Prior to this, she served as a General Partner in the Healthcare Technology Group at the Sprout Group from 1993 to 2005. Ms. LaPorte joined Sprout Group in 1993 and became General Partner in 1994. From August 1987 to January 1993, she served as a Principal at Asset Management Ventures. Ms. LaPorte served as a Financial Analyst at Credit Suisse Securities (USA) LLC and The First Boston Corporation. She served as Member of governing Board at The California Institute For Regenerative Medicine. She serves as a Director of Aesthetic Sciences, Lynx Therapeutics, Inc. and CellGate, Inc. She served in multiple senior leadership positions at Nodality Inc since July 2014 until July 2016. From 1994 to 2000, Ms. LaPorte served on the Board of Onyx Pharmaceuticals Incorporated. She served as Managing Director of New Leaf Venture Partners since 2005 until 2011. Ms. LaPorte has been a Director at TransOral Pharmaceuticals Inc. since October 25, 2005 and Nodality, Inc. since 2015. She served as the Chairman of FemRx, Inc. She served as Director of Adeza Biomedical Corp. since April 2002 and as a Director of Ehealthinsurance Services Inc. Ms. LaPorte served as a Director of VNUS Medical Technologies II, Inc. from April 1997 to July 2008. She served as Director of Transcept Pharmaceuticals, Inc. from October 2005 to April 2012. Ms. LaPorte served as a Director of Affymax, Inc. from 2001 to June 5, 2013. She served as a Director of ISTA Pharmaceuticals Inc from November 2002 to November 1, 2011. Ms. LaPorte served as a Director of Femrx, Inc. since April 1995. She served as Director of Intrabiotics Pharmaceuticals Inc. since January 1994, Blue292, Inc. Cytyc Prenatal Products Corp. since April 2002 and Prometheus Laboratories Inc. since August 2002. Ms. LaPorte served as a Director of Progen Pharmaceuticals, Inc.; Aradigm; and Sequana Therapeutics. She served as a Director of eHealth, Inc. from December 2000 to June 2007. She served as Director of Pearl Therapeutics, Inc. Ms. LaPorte was the President and Director of the Western Association of Venture Capitalists. She serves as Director of Elysium Therapeutics, Inc. Precipio Diagnostics and D2G Oncology. She holds an M.B.A. from the Stanford University Graduate School of Business, where she was an Arjay Miller Scholar and completed B.S. in Biology from Yale University.
公司職務
- 公司名稱Precipio, Inc.股票代碼PRPO職務Independent Non Executive Director共事同僚
- IDIlan DanieliFounder, President, CEO & Director
- RARichard Alvin SandbergIndependent Chairman of the Board
- AZAhmed Zaki SabetChief Operating Officer
- AAAyman A. MohamedChief Technology Officer
- MGMatthew GageChief Financial Officer
- MCMiri Chiko-RadomskiChief Legal Counsel & People Officer
- JCJeffrey CossmanIndependent Director
- DSDavid Seth CohenIndependent Director
- 公司名稱CERo Therapeutics Holdings, Inc.股票代碼CERO職務Independent Director共事同僚
- 公司名稱Q32 Bio Inc.股票代碼QTTB職務Independent Director共事同僚
- JPJodie Pope MorrisonCEO & Director
- MTMark T. IwickiIndependent Chairman of the Board
- LHLee H. KalowskiCFO & President
- SMShelia M. VioletteCo-founder, Chief Scientific Officer & President of Research
- DADavid AppuglieseSenior VP & Head of People
- MMMaria MarzilliChief Business Officer
- KDKathleen D. LaPorteIndependent Director
- MTMary T. ThistleIndependent Director
- DSDavid S. GrayzelIndependent Director
